Drug Store News25d
Generic drug suppliers weigh in on predictable, unpredictable category impact
and Alymsys (bevacizumab-maly), created under a partnership with mAbxience. By working with partners, Amneal controls costs and guarantees supplies. Late last year, the FDA approved Celltrion’s ...
Amneal Pharmaceuticals BLA submissions for denosumab biosimilars accepted by FDA
Amneal Pharmaceuticals (AMRX) “announced that the FDA has accepted for review its Biologics Licensing Application for two proposed denosumab ...
Business Wire12d
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...
Investing12d
Amneal seeks FDA nod for bone therapy biosimilars
The partnership between Amneal and mAbxience has previously resulted in the launch of ALYMSYS®, a bevacizumab biosimilar, in 2022. The proposed biosimilars could offer more affordable ...
Yahoo Finance12d
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Amneal and mAbxience currently partner on ALYMSYS ®, a bevacizumab biosimilar, which was launched in 2022. "Amneal is building its position in the U.S. biosimilars market as this next wave of ...